Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.9B | $292M | $103M | $105M | 5.9% | 8.0% | -14.3% |
| 2024 | $1.7B | $311M | $120M | $100M | 7.4% | 10.3% | 32.3% |
| 2023 | $1.6B | $255M | $91M | $60M | 6.0% | 16.9% | 36.6% |
| 2022 | $1.3B | $198M | $66M | $42M | 4.7% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,331.28 | 1,555.66 | 1,716.60 | 1,853.64 |
| Operating Revenue | - | 1,331.28 | 1,555.66 | 1,716.60 | 1,853.64 |
| Cost Of Revenue | - | 985.52 | 1,145.77 | 1,257.58 | 1,353.25 |
| Gross Profit | - | 345.76 | 409.89 | 459.01 | 500.39 |
| Operating Expense | - | 217.81 | 235.14 | 238.63 | 261.25 |
| Research And Development | - | 59.76 | 61.97 | 53.42 | 49.50 |
| Selling General And Administration | - | 158.05 | 173.17 | 185.20 | 211.75 |
| Total Expenses | - | 1,203.33 | 1,380.90 | 1,496.21 | 1,614.50 |
| Operating Income | - | 127.95 | 174.75 | 220.39 | 239.14 |
| Total Operating Income As Reported | - | 112.68 | 163.32 | 208.24 | 221.26 |
| EBITDA | - | 197.93 | 255.50 | 310.91 | 292.39 |
| Normalized EBITDA | - | 213.20 | 266.93 | 323.06 | 311.15 |
| EBIT | - | 105.94 | 156.66 | 199.88 | 161.72 |
| Interest Expense | - | 37.26 | 51.28 | 52.32 | 36.32 |
| Net Interest Income | - | -37.26 | -51.28 | -56.37 | -42.31 |
| Other Non Operating Income Expenses | - | 0.90 | -0.98 | -3.52 | -53.21 |
| Other Income Expense | - | -22.01 | -18.09 | -16.45 | -71.43 |
| Interest Expense Non Operating | - | 37.26 | 51.28 | 52.32 | 36.32 |
| Net Non Operating Interest Income Expense | - | -37.26 | -51.28 | -56.37 | -42.31 |
| Pretax Income | - | 68.68 | 105.38 | 147.56 | 125.40 |
| Tax Provision | - | 8.93 | 16.24 | 26.51 | 22.57 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -1.99 | -1.76 | -2.19 | -3.38 |
| Net Income Continuous Operations | - | 59.75 | 89.14 | 121.05 | 102.83 |
| Net Income From Continuing And Discontinued Operation | - | 66.38 | 90.65 | 119.90 | 102.81 |
| Net Income From Continuing Operation Net Minority Interest | - | 59.75 | 89.14 | 121.05 | 102.83 |
| Net Income | - | 66.38 | 90.65 | 119.90 | 102.81 |
| Net Income Common Stockholders | - | 66.38 | 90.65 | 119.90 | 102.81 |
| Net Income Including Noncontrolling Interests | - | 66.38 | 90.65 | 119.90 | 102.81 |
| Normalized Income | - | 73.03 | 98.81 | 131.02 | 118.22 |
| Diluted NI Availto Com Stockholders | - | 66.38 | 90.65 | 119.90 | 102.81 |
| Basic Average Shares | - | 33.13 | 33.32 | 33.60 | 34.74 |
| Diluted Average Shares | - | 33.36 | 33.76 | 35.65 | 35.59 |
| Reconciled Depreciation | - | 91.99 | 98.84 | 111.03 | 130.67 |
| Reconciled Cost Of Revenue | - | 985.52 | 1,145.77 | 1,257.58 | 1,353.25 |
| Total Unusual Items | - | -15.27 | -11.43 | -12.15 | -18.77 |
| Total Unusual Items Excluding Goodwill | - | -15.27 | -11.43 | -12.15 | -18.77 |
| Net Income Discontinuous Operations | - | 6.63 | 1.51 | -1.16 | -0.02 |
| Special Income Charges | - | -15.27 | -11.43 | -12.15 | -18.77 |
| Other Special Charges | - | - | - | - | 0.89 |
| Restructuring And Mergern Acquisition | - | 15.27 | 11.43 | 12.15 | 17.88 |
| Gain On Sale Of Security | -3.14 | -0.92 | 1.26 | - | - |
| Total Other Finance Cost | - | 1.92 | 3.54 | 4.06 | 5.99 |
| Other Operating Expenses | 0.51 | 1.19 | 2.11 | - | - |
| Earnings From Equity Interest | - | -7.64 | -5.69 | -0.78 | 0.55 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Integer Holdings Corporationthis co. | ITGR | $3.1B | 30.63β premium | 1.80 | 5.9% | 15.20 |
| ACADIA Pharmaceuticals Inc. | ACAD | $3.7B | 9.51 | 3.03 | 31.9% | 30.83 |
| Organon & Co. | OGN | $3.5B | 18.82 | 4.68 | 24.9% | 8.98 |
| ICU Medical, Inc. | ICUI | $3.4B | 4607.08 | 1.59 | 0.0% | 14.73 |
| Concentra Group Holdings Parent, Inc. | CON |
| - |
| - |
| - |
| - |
| - |
| - |
| $3.2B |
| 19.16 |
| 8.11 |
| 42.3% |
| 12.74 |
| Arcus Biosciences, Inc. | RCUS | $3.1B | -8.80 | 4.92 | -55.9% | -8.94 |
| National HealthCare Corporation | NHC | $2.9B | 24.47 | 2.75 | 11.2% | 13.71 |
| Privia Health Group, Inc. | PRVA | $2.7B | 117.50 | 3.65 | 3.1% | 50.35 |
| Supernus Pharmaceuticals, Inc. | SUPN | $2.6B | -67.30 | 2.44 | -3.6% | 58.94 |
| Peer Median | - | 18.99 | 3.34 | 7.2% | 14.22 | |